Here are the Form 4 insider transactions from Eastman Chemical Company (EMN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EMN filings page.
Eastman Chemical CEO and board chair Mark J. Costa reported a tax-related share disposition. On the payout of performance shares for the 2023-2025 performance period, 25,260 shares of common stock were withheld to cover tax obligations at a price of $80.26 per share. After this withholding, Costa directly owns 497,929 shares of Eastman Chemical common stock, and indirectly holds 3,227 shares through an ESOP arrangement.
Eastman Chemical executive Stephen Glenn Crawford, EVP and Chief Technology and Sustainability Officer, had 4,720 shares of common stock withheld on February 18, 2026 at $80.26 per share to cover tax obligations from a 2023–2025 performance share payout. After this tax-withholding disposition, he holds 67,714 common shares directly, plus additional indirect holdings through 401(k) and ESOP accounts for himself and his spouse.
Eastman Chemical executive Brad A. Lich reported an equity award of company stock. On February 11, 2026, the EVP & CCO acquired 18,861 shares of Eastman Chemical common stock at $0 per share as a grant based on performance for the three-year 2023–2025 period.
After this award, Lich beneficially owned 102,348 common shares directly, plus 2,594 shares indirectly through a 401(k) plan and 1,251 shares indirectly through an ESOP, reflecting his combined direct and plan-based holdings in Eastman Chemical.
McLain William Thomas Jr. reported acquisition or exercise transactions in a Form 4 filing for EMN. The filing lists transactions totaling 15,883 shares. Following the reported transactions, holdings were 69,784 shares.
Eastman Chemical executive Stephen G. Crawford received an equity award of company stock. On February 11, 2026, he acquired 12,133 shares of Eastman Chemical common stock at a price of $0 per share, reported as a grant or award tied to performance.
This award, based on the determination of performance shares earned for the three-year 2023–2025 period, increased his direct holdings to 72,434 common shares. He also reports indirect ownership through benefit and retirement plans: 459 shares by a 401(k) plan, 296 shares by his spouse in an ESOP, 1,134 shares by an ESOP, and 64 shares by his spouse in a 401(k) plan.
Stewart Michelle Renee reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Controller and Chief Accounting Officer Michelle Renee Stewart received an award of 3,309 shares of common stock on February 11, 2026 at a price of $0 per share. The award reflects the determination of performance shares earned for the three-year 2023–2025 performance period. Following this grant, she directly owns 8,272 Eastman Chemical common shares.
Costa Mark J reported acquisition or exercise transactions in a Form 4 filing for EMN. The filing lists transactions totaling 64,192 shares. Following the reported transactions, holdings were 523,189 shares.
Eastman Chemical executive Julie A. McAlindon reported an equity award of company stock. On February 11, 2026, she acquired 7,280 shares of Eastman Chemical common stock at a price of $0 per share, reported as a grant, award, or other acquisition.
The footnote explains this reflects the determination of performance shares earned for the three-year 2023–2025 performance period, meaning the award was tied to multi‑year performance goals. After this grant, McAlindon directly beneficially owned 20,011 common shares, and indirectly beneficially owned an additional 887 shares through an ESOP.
Caveness Michelle H reported acquisition or exercise transactions in a Form 4 filing for EMN. The filing lists transactions totaling 1,937 shares. Following the reported transactions, holdings were 8,183 shares.
Eastman Chemical executive Brian Travis Smith acquired 10,589 shares of common stock on February 11, 2026 through a performance award. The shares were granted at a price of $0 per share following the determination of performance shares earned for the 2023–2025 period.
After this award, Smith directly beneficially owns 27,321 shares of Eastman Chemical common stock.
Eastman Chemical senior vice president Adrian James Holt received an equity award linked to company performance. On 02/11/2026, Holt acquired 2,297 shares of Eastman Chemical common stock at a price of $0 per share. These shares were granted following the determination of performance shares earned for the three-year 2023–2025 performance period, and are held as direct beneficial ownership.
Eastman Chemical CEO and Board Chair Mark J. Costa reported an insider equity transaction involving company stock on February 4, 2026. He exercised 48,649 employee stock options at an exercise price of $65.16 per share, receiving the same number of Eastman Chemical common shares.
A portion of these shares, 43,638, was withheld by Eastman Chemical to cover the option exercise price and tax withholding obligations in a net exercise, which the filing states does not represent a sale by Costa. After these transactions, Costa directly owned 458,997 shares of common stock, with an additional 3,231 shares held indirectly through an ESOP.
Eastman Chemical Company’s EVP and CFO, William Thomas McLain Jr., reported an option-related share transaction. On 02/04/2026 he exercised employee stock options for 3,013 shares of common stock at an exercise price of $65.16 per share.
To cover the option exercise price and tax withholding in a “net exercise,” 2,636 shares were withheld by Eastman Chemical and not sold on the market. After these transactions, he directly beneficially owned 53,901 shares of Eastman Chemical common stock.
Eastman Chemical Company reported an equity award to executive officer Stephen G. Crawford, EVP, Technology Projects. On 01/02/2026, he received 34,193 restricted stock units (RSUs), each representing a contingent right to receive one share of Eastman Chemical common stock. These RSUs were reported as derivative securities beneficially owned directly.
The RSUs carry a conversion price of $0 and are scheduled to vest and pay out in unrestricted shares of common stock on February 2, 2027, subject to Mr. Crawford’s continued employment. After this grant, he beneficially owns 34,193 derivative securities in the form of RSUs tied to Eastman Chemical common stock.